Haemonetics downgraded at Needham on vascular closure device competition
Source: SeekingAlpha
2025-12-15 14:56:47 ET
More on Haemonetics
- Haemonetics Is Still Undervalued, Even After The Rally
- Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript
- Intuitive Surgical downgraded as Citi previews 2026 in MedTech
- Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance
- Seeking Alpha’s Quant Rating on Haemonetics
Read the full article on Seeking Alpha
For further details see:
Haemonetics downgraded at Needham on vascular closure device competition
Haemonetics Corporation
NASDAQ: HAE
HAE Trading
-0.1% G/L:
$62.195 Last:
9,782 Volume:
$62.37 Open:
HAE Latest News
February 23, 2026 04:15:00 pm
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
February 20, 2026 04:05:00 pm
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
HAE Stock Data
$2,748,315,639
45,616,277
0.08%
124
N/A
Medical Equipment & Supplies
Healthcare
US
Boston
